HFrEF

11 · 20 / page

Ask MedXY AI

Latest news

Tag

CardiologyHFrEFMavacamten

Targeting Skeletal Muscle Myosin ATPase May Reduce Resting Energy Waste in Heart Failure With Reduced Ejection Fraction

By MedXY|May 6, 2026

An ex vivo human skeletal muscle study suggests that myosin ATPase inhibition with mavacamten normalizes excessive resting ATP consumption in HFrEF myofibres, identifying a mechanistically novel strategy to address peripheral metabolic inef

Only 1 in 5 Veterans with Heart Failure Achieve Recommended Quadruple Therapy Within 3 Years—What This Means for Clinical Practice

CardiologyGDMT

HFrEF

Latest news

Targeting Skeletal Muscle Myosin ATPase May Reduce Resting Energy Waste in Heart Failure With Reduced Ejection Fraction

Only 1 in 5 Veterans with Heart Failure Achieve Recommended Quadruple Therapy Within 3 Years—What This Means for Clinical Practice

Residual Clinical Risk and Economic Burden in HFrEF: Insights from the Quadruple Medical Therapy Era

Substantial Residual Risk and High Costs Persist in HFrEF Despite Optimal Quadruple Therapy at Discharge

Empagliflozin Enhances Cardiovascular Protection in HFrEF Patients with Low Serum Magnesium: Evidence from EMPEROR-Reduced

PDE9 Inhibition with CRD-740 Safely Elevates cGMP Levels in HFrEF: Results from the CARDINAL-HF Trial

Declining Kidney Function Often Precedes Heart Failure Hospitalization in HFrEF — Track eGFR Slopes, Not Just Thresholds

Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR Phase 3 Trial

Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial

Five Key Lessons From the DIGIT-HF Trial: Revisiting Digitoxin in HFrEF Management

Digitoxin Revisited: A Renewed Therapeutic Avenue for Advanced Heart Failure Patients